Caprock Group LLC Acquires New Position in Elevance Health, Inc. $ELV

Caprock Group LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,140 shares of the company’s stock, valued at approximately $1,638,000.

Several other institutional investors have also modified their holdings of ELV. MGO One Seven LLC increased its holdings in Elevance Health by 2.0% during the 2nd quarter. MGO One Seven LLC now owns 2,755 shares of the company’s stock worth $1,072,000 after purchasing an additional 53 shares during the period. Axxcess Wealth Management LLC grew its position in shares of Elevance Health by 27.0% during the second quarter. Axxcess Wealth Management LLC now owns 1,436 shares of the company’s stock worth $558,000 after buying an additional 305 shares in the last quarter. Sagespring Wealth Partners LLC increased its stake in shares of Elevance Health by 18.0% during the second quarter. Sagespring Wealth Partners LLC now owns 1,580 shares of the company’s stock worth $615,000 after buying an additional 241 shares during the period. Mutual Advisors LLC raised its holdings in Elevance Health by 17.0% in the second quarter. Mutual Advisors LLC now owns 2,370 shares of the company’s stock valued at $922,000 after acquiring an additional 345 shares in the last quarter. Finally, Harbor Asset Planning Inc. acquired a new stake in Elevance Health in the second quarter valued at approximately $107,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Trading Up 3.1%

NYSE:ELV opened at $346.49 on Friday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The stock’s 50 day simple moving average is $352.22 and its 200-day simple moving average is $331.73. The firm has a market cap of $76.47 billion, a P/E ratio of 13.79, a PEG ratio of 1.87 and a beta of 0.50.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is currently 27.23%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Analysts Set New Price Targets

ELV has been the topic of a number of recent analyst reports. Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price objective on the stock. in a research report on Tuesday, February 3rd. Morgan Stanley lowered their target price on shares of Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $332.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Finally, Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.